2. Executive Summary
Medical Diagnostic accounts for 10% of the healthcare industry in India
Diagnostics market comprises of
Market – Diagnostic Services Market : Estimated at INR 37.9 bn in 2008
– Diagnostic Products Market: Estimated at INR 15.8 bn 2008
India has more than 40,000 laboratories
Drivers: Increase in lifestyle‐related diseases, changing demographics, growth in medical
Drivers & outsourcing, medical tourism, nascent but growing medical insurance, rising PE/VC investments
Challenges
g Challenges: Difference in import duty on diagnostic kits for public and private sector and Lack of
accreditation/certification of diagnostic centers
Diagnostic equipments market is regulated by both central and state government
Major governing authorities include Directorate General of Health Services, Indian Food and Drug
Rules and
Rules and g g g
Administration, Central Drugs Standard Control Organization, Drug Controller General of India
Regulatory process for diagnostics equipment is segmented into
Regulations
– Critical ‐ Products used for the diagnosis of HIV, HBsAg, HCV, Blood grouping reagents, malaria tests
– Non critical ‐ Other diagnostics products
Manufacturers need an import licence and product registration certificate to import diagnostic
equipments
Diagnostic test services market is highly fragmented with many unorganized players
– Some of the major players are Metropolis Health Services, SRL Ranbaxy, Piramal Diagnostics, Dr Lal PathLabs,
Competition Thyrocare, Apollo Hospitals
Foreign players (like Roche Abbott J&J ) account for 64% share in diagnostic equipment market
Foreign players (like Roche, Abbott, J&J ) account for 64% share in diagnostic equipment market
– Some of the major domestic manufacturers are Transasia, Tulip Group and Agappe Diagnostics
MEDICAL DIAGNOSTICS – INDIA.PPT 2
3. • Market Overview
• Drivers & Challenges
Drivers & Challenges
• Rules & Regulations for
Manufacturers/Suppliers
• Competition
•K D l
Key Developments t
MEDICAL DIAGNOSTICS – INDIA.PPT 3
4. Indian diagnostics market is witnessing significant growth with
major contribution from the In‐Vitro Diagnostic (IVD) segment
Market Overview Diagnostic Test Services Market
• Indian diagnostic market comprises of INR bn +20%
Diagnostic test services market 40 37.9
Diagnostic products/instruments market 31.6
31 6
30 26.3
• Diagnostic market accounts for 10% of healthcare
20 In 2008, IVD
sector
10 services market
• India currently has over 11,500 hospitals and 40,000
was INR 36 bn
diagnostic laboratories
diagnostic laboratories 0
• About 70% of the treatments in India are based on lab 2006 2007 2008
diagnostic tests Market size estimation is difficult as diagnostic market is highly unorganized
IVD Test Segments (2008) IVD Instruments & Reagent Market
BioChemistry INR bn
4% Immunology 20 +18%
5%
3% 15.8
6% Haematology 15
37% 12.8
Critical care 11.4
11 4
7%
Urine Routine 10
14% Others 5
Microbiology
0
24% Coagulation 2006 2007 2008
MEDICAL DIAGNOSTICS – INDIA.PPT 4
5. Technological developments has led to the diagnosis of a wide
spectrum of infectious diseases
Diagnostics Consumption & trends Type of testing CAGR % (2004‐08)
Infectious Disease
Tuberculosis Increasing ELISA‐90%; Rapid‐10% 11.0
HIV Increasing ELISA‐65%; Rapid‐35%
d 10.6
Malaria Increasing Immunodiagnostic‐m 9.4
Hepatitis B Steady ELISA‐65%; Rapid‐34% Agglutination methods‐1% 7.7
Hepatitis C Steady ELISA‐80%; Rapid‐20% 7.7
Dengue
D Steady
S d ELISA‐65%; Rapid‐35%
ELISA 65% R id 35% 7.6
76
Syphilis Steady ELISA‐65%; Rapid‐35% 5.7
Typhoid Steady ELISA‐65%; Rapid‐35% 5.6
Hormones
Reproductive hormones Increasing ofLH‐35%, FSH and prolactin kits‐65% 8.6
Thyroid Increasing ELISA‐90%, RIA and Chemiluminescence‐10% 7.7
Others
Blood Grouping reagents Steady Haemagglutination 5.7
Pregnancy diagnosis Steady Immunochromatography/ Latex 5.7
Cancer Markers Steady Fluorescence, ELISA, Chemiluminescence 5.7
Nascent market. Maximum penetration observed only in Polymerase Chain Reaction (PCR) based technologies.
Molecular Diagnostics
Companies offering immunodiagnostics have been largely importing equipments
This shows that the market for diagnostic tests has been rising
MEDICAL DIAGNOSTICS – INDIA.PPT 5
6. • Market Overview
• Drivers & Challenges
Drivers & Challenges
• Rules & Regulations for
Manufacturers/Suppliers
• Competition
•K D l
Key Developmentst
MEDICAL DIAGNOSTICS – INDIA.PPT 6
7. Drivers & Challenges
Drivers
Increase in lifestyle‐related diseases
Challenges
Changing demographics
Difference in import duty on
Growth in medical outsourcing diagnostic kits for public and private
sector
Rapid growth of India as a destination
Rapid growth of India as a destination Lack of accreditation/certification of
/
for medical tourism diagnostic centers
Increasing penetration of medical
insurance
Rising PE/VC investments
MEDICAL DIAGNOSTICS – INDIA.PPT 7
8. Mounting instances of lifestyle diseases in urban areas and the
demand for quality diagnosis
Growth in lifestyle related diseases Impact
• Increasing instances of lifestyle diseases is an urban phenomenon, especially among the young
and working class in metropolitan areas
• Lifestyle diseases such as cardiac ailments, diabetes etc. require expensive diagnostic tests
making this segment increasingly lucrative for players
Prevalence of chronic lifestyle diseases in India
P l f h i lif t l di i I di Diagnostic Tests Cost Comparison
Di ti T t C t C i
% of Population 2005 USD/Treatment
4.91%
5 2015 500
418
4 3.70% 400
3.31%
3 2.80% 300 280
2 200 150
1 100
0.18% 0.20%
0 18% 0 20% 12 5
0 0
Cardiac Diabetes Cancer Hepatitis Thyroid Cardiac Diabetes Cancer
A
MEDICAL DIAGNOSTICS – INDIA.PPT 8
9. Changing demographic scenario in India is expected to drive
demand
Changing demographics Impact
• Increase in average life expectancy and growth in elderly population is expected to boost
demand
• Large scale movement of rural population to urban centers will also opt for these services
Average Life Expectancy Population (Age 65 years and above)
years %
5.3 5.8
100 6 4.7
63.3 65.1 66.0
4
50
2
0 0
2000-04 2005-09 2006-10 2000 2005 2010
MEDICAL DIAGNOSTICS – INDIA.PPT 9
10. Strong outsourcing opportunities due to technological
enhancements and cost benefits
Growth in outsourcing Impact
• Diagnostics outsourcing has been growing due to technological upgradation of equipment in
Indian laboratories meeting international standards
• Cost benefits have also played a major role
• Specialized tests like molecular diagnostics or hormone related tests cost 70‐80% less in India
than in US
• Medical institutions from US and UK have been outsourcing a bulk of tests
Outsourcing opportunity specifically from the UK, in healthcare sector, is pegged at around USD 800 mn
• India provides cost arbitrage :
Tests Cost in US/UK (USD) Cost in India (USD) % Difference
Blood tests, X rays and ultrasounds
Blood tests, X‐rays and ultrasounds 574 84 583
Magnetic resonance imaging (MRI) scan 700 60 1067
Thyroid profile blood test 30‐50 5 500‐900
Note: The rates are indicative
MEDICAL DIAGNOSTICS – INDIA.PPT 10
11. Medical tourism is providing supplemental revenues for the
diagnostic market
Medical tourism in India Impact
• In addition to growing domestic demand, medical tourism is generating additional revenue for
diagnostics services
• Medical tourism has been growing at 30% and is expected to become at USD 2 bn industry by
2010
• Some part of medical tourism market is expected to accrue to the diagnostics market, primarily
benefiting the hospitals with diagnostic centers
•M i d i
Main drivers and challenges for medical tourism are ‐
d h ll f di l t i
Drivers Challenges
• Significant savings • Inadequate air connectivity
• World‐class facilities • Visa requirements from most countries
q
• Quality and experience of medical professionals • Medico legal jurisdictions
• Minimal waiting time • Country specific restrictions
• Large market of uninsured in developed countries
MEDICAL DIAGNOSTICS – INDIA.PPT 11
12. Growing penetration rates of health insurance has made quality
diagnostic services more affordable
Rising health insurance levels Impact
•In India, penetration of health insurance is very low but growing:
More families from middle class are now purchasing health insurance
20% of population is likely to have medical insurance by 2015 compared to current 2%
Additionally, many companies are providing health insurance coverage to employees
thereby driving penetration
•Increasing insurance coverage provide additional revenue to the diagnostics centres
g g p g
Insurance companies tie up with diagnostic centres to provide better health assessment
services (medical screening, diagnostic testing) to life insurance candidates
– Birla Sun Life Insurance Company Ltd entered into a partnership with Quest Diagnostics India Private Ltd.
– ICICI Lombard entered into an insurance partnership with Manipal, Fortis and Apollo Group
Health Insurance Premium
INR bn
1,000 950
+35%
500
212
47
0
2008 2013 2018
MEDICAL DIAGNOSTICS – INDIA.PPT 12
13. Large scale investments from PE/VC firms towards capitalizing
on the growth prospects in the market
Increased focus of PE/VC firms Impact
• Private equity players are bullish on the healthcare industry in India
• In 2008, the healthcare sector accounted for 13% of total investments amounting to USD
5570.48 mn
• Apart from hospitals and pharma, private equity players are also showing interest in diagnostic
centers in India
% Amount
Date
D t Investor
I t Target
T t
Stake USD mn
ePlanet Ventures and HSBC
Nov 2007 Trivitron n.a. 11
Private Equity (Asia) Ltd
2007 Sequoia Capital India
Sequoia Capital India Dr Lal PathLabs
Dr Lal PathLabs n.a.
na 4
Jun 2006 Bennett, Coleman and Co. Thyrocare n.a. n.a.
May 2006 ICICI Ventures Metropolis Health Services Ltd n.a. 8
2005 Sequoia Capital India
q p Dr Lal PathLabs 26 6
MEDICAL DIAGNOSTICS – INDIA.PPT 13
14. Biased government regulation and the lack of accreditation
affecting the of quality services are the major barriers
Difference in import duty on diagnostic kits for public and private sector Impact
• The import structure has been so formulated that it favors the public sector
• Private sector is faced with the issue of providing services at competitive prices across income
groups and are often reduced to providing services only to a niche market
Public Private
• In order to import equipments and reagents • For importing diagnostic equipments a duty of 19.8 ‐
Government hospitals do not require a an import
Government hospitals do not require a an import 21.7% is levied
license; a duty of 5% is levied • Equipments and supplies are procured based on
• Equipment and supplies are procured through quality and price, leading to cost escalations
tenders with price being the foremost basis of
decision making
Lack of accreditation/certification of diagnostic centers Impact
• Lack of accreditation or certification has led to a large pool of medical centers with minimal
g p
focus on the quality, which is in contrast to mandatory requirements for other aspects of
healthcare such as hospitals, doctors, nurses and even pharmacies
• Less than 1% of the total laboratories are accredited
14 have College of American Pathologists (CAP) accreditation
45 have National Accreditation Board of Laboratories (NABL) accreditation
MEDICAL DIAGNOSTICS – INDIA.PPT 14
15. • Market Overview
• Drivers & Challenges
Drivers & Challenges
• Rules & Regulations for
Manufacturers/Suppliers
• Competition
•K D l
Key Developments t
MEDICAL DIAGNOSTICS – INDIA.PPT 15
16. Diagnostic equipment manufacturers are highly regulated by the
central and state government bodies
Major governing bodies
Government Authorities Operation
Oversees activities of the Indian Food and Drug Administration (FDA) and Central Drugs
Oversees activities of the Indian Food and Drug Administration (FDA) and Central Drugs
The Directorate General of Health Services
Standard Control Organization (CDSCO)
Regulates the manufacture of all diagnostic kits and reagents as it belongs to the
FDA and CDSCO
category of drugs
Responsible for approval of licenses of specified categories of drugs and diagnostics
Drug Controller General of India
Drug Controller General of India
products
They monitor the quality of drugs and diagnostics products that are manufactured by
State drug offices / State FDA’s
respective State units and those marketed in the State
Segmentation of products
Products used for the
diagnosis of HIV, HBsAg,
Critical Devices
HCV, Blood grouping
reagents, malaria tests
Diagnostic Products
Diagnostic Products
Non‐Critical Devices Other diagnostics products
All diagnostics products manufactured or sold in India requires a license
MEDICAL DIAGNOSTICS – INDIA.PPT 16
17. The difference in regulations for critical and non‐critical
diagnostics devices has led to lack of quality control
Regulatory process for diagnostics equipments Quality
checks are
Manufact
conducted
uring
by
y
Application is
A li ti i license
li
submitted to the granted
Critical Devices National
Drugs Controller after an
Institute
General of India audit of
of
Communica
manufact
ble
3‐6 months uring unit
disease
• Test manufacturing license or test batch evaluation is not required
Non Critical Devices • No inspections needs to be carried out by the central authorities
• The application is to be filed only with the State drug offices
The application is to be filed only with the State drug offices
Lack of sufficient quality control measures has led to substantial number of questionable products in the market
MEDICAL DIAGNOSTICS – INDIA.PPT 17
18. Manufacturers need an import license and product registration
certificate from the Central Drugs Standard Control
Regulations Related to Imports
CDSCO is responsible for quality control of imported products as well as the licensing of new products
Registration Certificate Import License
• Registration Certificate: Application in respect of the • Documentation
premises and the devices to be imported Form‐9 is to be forwarded by the manufacturer and should be
• Submission: The application is reviewed by the Drugs attested by the Indian Embassy in the manufacturers country
Controller General GMP (Good Manufacturing Practices) certificate
• Registration fee: USD 1000 per product to be registered Company Registration certificate
• Other Documents: Bank slips showing requisite fee paid, Form Free Sales Certificate in the country of manufacture
40 Power of Attorney to the Indian Agent/Office and dossiers Manufacturing License
Manufacturing License
• Duration: The registration process takes 9 months Country of Origin Certificate
• Forwarded by the manufacturer, importer or the agent in List of countries where the product is already being exported
India
ISO / TUV / CE certificate
Batch Release Certificate (for any one batch)
QC certificates (for any one batch)
Other requirements for imported medical diagnostic equipments are ‐
• A batch release certificate for the specific goods that have been imported
• Shelf‐life certificate which must state that the goods have a shelf‐life of more than 60% at the time of landing
g g
• Certificate of Analysis for the products supplied
MEDICAL DIAGNOSTICS – INDIA.PPT 18
20. • Market Overview
• Drivers & Challenges
Drivers & Challenges
• Rules & Regulations for
Manufacturers/Suppliers
• Competition
•K D l
Key Developments t
MEDICAL DIAGNOSTICS – INDIA.PPT 20
21. Organized pathlabs are rapidly expanding using the hub and
spoke model, including small, independent labs in the network
Diagnostic Testing Market Structure Hub and Spoke Model
• Highly fragmented with ~40,000 laboratories:
CC CC
Hospitals: 43%
Independent labs: 52%
CC CC
• Among the labs in India
Automated – 5% Reference
Semi ‐ Automated – 38% Lab
Manual 58%
Manual – 58% Satellite
Satellite Satellite
S t llit
Lab Lab
• Organized players account for 10% of market and
expanding with ‘hub and spoke’ model:
Reference labs act as regional hubs and are usually located CC CC CC CC
in large metros
Collection centres are located in hospitals, nursing homes,
pathology labs, doctor’s clinics etc.
Satellite labs and collection centres are either owned or • Reference labs: Hub with comprehensive or specialized testing
franchised capability
• As organized players grows their share small
As organized players grows their share, small, • Satellite labs: Limited testing capability; ‘feed’ reference labs
Satellite labs: Limited testing capability; feed reference labs
independent labs are: • Collection centres (CC): Collect samples for forwarding to
Becoming franchisees in the hub and spoke model either a satellite lab or reference lab
Partnering with large chains on referral basis • A variation in this model is the absence of satellite labs and
Getting acquired by large chains, which lowers the cost of the existence of only reference labs and collection centres
expansion and start‐up time for the latter
MEDICAL DIAGNOSTICS – INDIA.PPT 21
22. Major Players – Diagnostic Test Services Market (1/2)
Company Overview Business Outlook
Apollo Hospitals • Started in 1983 • Entered into a JV with Amcare Labs, an
• Diagnostic facilities in their subsidiary Apollo Clinics affiliate of Johns Hopkins International of
• Facilities allow for investigation in Biochemistry Haematology
Facilities allow for investigation in Biochemistry, Haematology, the US, to set up a diagnostic laboratory in
Clinical Pathology, Microbiology, X‐ray, Ultrasound with Color Hyderabad at an investment of USD 2.2 mn
Doppler, ECG, Echo Cardiography and Treadmill
Dr Lal PathLabs • Started in 1977 • Established an international alliance with
• 40 labs and 500 sample collection centers Quest Diagnostics Nicholas Institute for
• Accreditation: NABL, CAP testing
• Planning to set up 50 labs and 1000
collection centers by 2012
• Expand operations in southern and western
regions investing INR 600 mn
• Planning to invest INR 100 mn in brand
l b d
building
Metropolis Health • Started in 1981 • Growing inorganically
Services • 10000 laboratories across 125 cities globally, 13 laboratories in • It is looking at overseas expansion as well as
India, 350 collection centers
, outsourcing opportunities
g pp
• Capability to carry over 3600 routine investigations with over • Plans on increasing their portfolio to 9 more
100 technologies ‐ e.g. biochip, DNA sequencing, pathology, labs
radiology • Targeted revenue of INR 5 bn by 2010
• ICICI Ventures owns 18% of the company • In 2008, acquired two labs in North India
• Accreditation: CAP NABL
Accreditation: CAP, NABL and a majority stake in Bangalore based RV
and a majority stake in Bangalore based RV
Diagnostic Laboratory
Note: This list is not exhaustive
MEDICAL DIAGNOSTICS – INDIA.PPT 22
23. Major Players – Diagnostic Test Services Market (2/2)
Company Overview Business Outlook
Piramal Diagnostics • Started in 1988 • Planning to invest INR 2.5 bn to expand its
/ Wellspring • 104 diagnostic centers in 48 cities, 300 collection centers diagnostic chain in 75 urban centers by 2010
• Carries out over 1500 tests
Carries out over 1500 tests • Acquired Minrad International Inc for USD
q
• Accreditation: NABL, CAP 40 mn
Super Religare • Started in 1996 • Tie‐ups with UK‐based organizations for
Laboratories • 35 labs, 800 collection centers distributed in 400 towns across outsourcing
Limited/SRL
/ the country and 7 franchisee lab • Plans on developing 2‐3 reference
• Caters to 25000 doctors, 650 hospitals and ~ 1000 smaller laboratories in 2009
Ranbaxy
pathology labs and carries out 34000tests/day based on 95 • Expansion budget is pegged at INR 1.5bn
technologies • In 2008, acquired Dubai‐based Mena
• Accreditation: CAP, NABL, CLSI, GCLP Healthcare for USD 20 mn
• Reported total revenues of INR 804 mn in FY2007
p
Thyrocare • Started in 1995 • Centralized operations through a single
• Carries out 30000 test/day, over 600 franchised collection laboratory model, located in Navi Mumabi
centers • Only player expanding through a 100 %
• Accreditation: CAP, NABL franchisee model
Note: This list is not exhaustive
MEDICAL DIAGNOSTICS – INDIA.PPT 23
24. Manufacturers – IVD Products/Instruments Market
Players in the market IVD Products Market Share (2008)
•The IVD products market in India is primarily
y g p
dominated by foreign companies
•Global IVD companies like Roche Diagnostics,
Abbott, J&J, Siemens Healthcare Diagnostics, 36%
Beckman Coulter have strong presence in the
Indian market
I di k t
64%
•Domestic players have forayed into the market
and are establishing themselves by producing
q yg
cost effective and quality goods
•60% of diagnostic medical equipment and Foreign Players
supplies is imported Domestic Players
•Low‐cost reagent kits are being imported from
China, Taiwan, and Korea
MEDICAL DIAGNOSTICS – INDIA.PPT 24
25. Major Domestic Players – Diagnostic Equipment Manufacturing
Market (1/3)
Company Overview Business Outlook
Agappe Diagnostics • Reagents: Clinical chemistry, SyRe Biochemistry), SyRe • Focusing on the export markets with plans
(Immunoturbidimetry), Controls/ Calibrators, serology, of establishing a subsidiary in Dubai under
hemoscreen, coagulation, Urinal analyzer, infectious rapid card Agappe Middle East LLC
test, infectious ELISA, hepatitis markers, torch panel, • Also plans to expand operations to Africa
Glucometer and Europe
• Instruments: Clinical Chemistry Analyzer, Hematology Analyzer, • Launched Biolis 12i , a fully automatic
Coagulation Analyzer, Sodium & Potassium Analyzer analyser as well as Cystatin C, a more
sensitive instrument for the estimation of
Glomurular Filtration Rate
J. Mitra • Rapid test kits: HIV range, HCV range, HBV range, Malaria • Focuses on Point‐of‐Care (POC) for
range infectious diseases like HIV and malaria
• ELISA test kits: HIV range, HCV range, HBV range, Dengue • Mass production at affordable prices
range, LEPTO range, TB range
range LEPTO range TB range • Partnered with WHO for product sales
Partnered with WHO for product sales
• Confirmatory Tests, Blood Grouping Range • Market leader in HIV diagnosis equipment
Orchid Biomedical • Fertility range, Infectious diseases range, Parasitology range • Focuses on POCs for infectious diseases
Systems (Tulip • Mass production at affordable prices
Group) • Partnered with WHO for product sales
Partnered with WHO for product sales
Note: This list is not exhaustive
MEDICAL DIAGNOSTICS – INDIA.PPT 25
26. Major Domestic Players – Diagnostic Equipment Manufacturing
Market (2/3)
Company Overview Business Outlook
RFCL • IVD, animal healthcare, laboratory solutions and custom • Adopted an inorganic growth path ‐
synthesis In April 2008, acquired Bremer Pharma
In September 2008, acquired US based
Mallinckrodt Baker for USD 340 mn
In January 2008, acquired Godrej Medical
Diagnostics and Alved Pharma & Foods
In July, 2007 acquired Wipro Biomedical
• Targeted revenue of INR 5 bn by 2010
Span Diagnostics • Diagnostic reagents & kits: Blood banking products, clinical • It is a leader in Sphilis and thyroid diagnosis
Ltd. chemical reagents, hematology, infectious diseases serology, equipment
histopathology, antibiotic discs
• Instruments: Biochemistry, ELISA, Hematology,
Chemiluminescence
Transasia Bio‐ • Related to bio‐chemistry, hematology, urine analysis, • Plans to expand it’s existing product range
Medicals coagulation, ESR, immunology, liquid handling system and venture into microbiology and
veterinary science
Tulip Group • Immunology Reagents, Cardiac Markers, Cancer Markers, • It is one of the leader sin syphilis, typhoid,
Parasitology & Infectious Disease Range
Parasitology & Infectious Disease Range malaria, reproductive hormones, blood
malaria reproductive hormones blood
• Instruments ‐ Coagulometers, ELISA reader & washer grouping reagents, cancer markers and
tuberculosis diagnostic equipment
Note: This list is not exhaustive
MEDICAL DIAGNOSTICS – INDIA.PPT 26
27. Major Domestic Players – Diagnostic Equipment Manufacturing
Market (3/3)
Company Overview Business Outlook
Xcyton • Immunodiagnostic kits: HIV CheX and HEP CheX C, JEV CheX, • Strategic partnership with Qualigens fine
CYSTI‐ CheX, Dengue – CheX chemicals in order to market their HIV
• Molecular diagnostic kits
g and hepatitis diagnostic kits
p g
Yashraj Biotech • Antigens: Customized monoclonal and polyclonal antibodies • Focusing on reducing costs of molecular
diagnostics through innovative technology
diagnostics through innovative technology
Other Player : Accurex Biomedical, Bhat Biotech, Medsource Ozone Biomedicals Pvt. Ltd., Trivitron
Note: This list is not exhaustive
MEDICAL DIAGNOSTICS – INDIA.PPT 27
28. • Market Overview
• Drivers & Challenges
Drivers & Challenges
• Rules & Regulations for
Manufacturers/Suppliers
• Competition
• Ke De elopments
Key Developments
MEDICAL DIAGNOSTICS – INDIA.PPT 28
29. Key Developments
Date Development
17‐Mar‐09 Roche Diagnostics, a swiss based company, plans on consolidating their position in the Indian market in 2009. They plan on
expanding their reach through innovative diagnostic tests such as the NT‐proBNP and K‐RAS mutation tests related to
colorectal cancer.
10‐Feb‐09 Aloka Trivitron Medical Technologies, a medical equipment manufacturing JV of Aloka, Japan and Trivitron healthcare began
production of Aloka SSD 500, portable ultrasound scanner from its facility at Poonamallee in Chennai. It plans on developing
high quality products on a cost effective basis catering primarily to the developing nations.
06‐Oct‐08 Wipro an IT giant has entered the medical diagnostics market through its subsidiary Wipro Biomed. They have tied up with
GE to develop cutting‐edge technology in order to generate a unique selling price. Wipro is planning to focus on
GE to develop cutting‐edge technology in order to generate a unique selling price Wipro is planning to focus on
telemedicine, especially in the diagnostic radiology.
10‐Mar‐08 Sneha Diagnostics plans on developing 10 state‐of‐the‐art medical diagnostics centres across Andhra Pradesh by 2009. A
capital investment of INR 50 mn is expected towards this expansion venture.
09‐Jan‐08 RFCL Limited, an ICICI venture company acquired Godrej Medical Diagnostics. This led to partnerships with QBC Diagnostics,
USA, Asia Gen Corporation, Taiwan and Uritest Medical Electronic Co Ltd, China allowing them to expand their reach.
USA Asia Gen Corporation Taiwan and Uritest Medical Electronic Co Ltd China allowing them to expand their reach
MEDICAL DIAGNOSTICS – INDIA.PPT 29
30. Thank you for your time
For an updated report or any customized research requirements, please contact:
Gaurav Kumar
E‐Mail: gaurav.kumar@netscribes.com; sales@netscribes.com
Phone: +91 33 4064 6214; +91 983 030 9715
Netscribes’ Services:
RESEARCH & ANALYTICS
RESEARCH & ANALYTICS MARKET INTELLIGENCE
MARKET INTELLIGENCE CONTENT SOLUTIONS
CONTENT SOLUTIONS
Investment Research Market Monitoring & Competitive Social Media Marketing
Enterprise Market Research Intelligence Marcom Support Services
Patent Research Sales & Prospect Intelligence Content Management Services
Syndicated Market Research
S di t d M k t R h Listening & Media Monitoring
Li t i & M di M it i Book Packaging Services
B kP k i S i
Brand Surveillance
For further details, visit us at: www.netscribes.com
About Netscribes
Netscribes supports the organic and inorganic growth objectives of global corporations through a combination of Enterprise Market,
Investment & Patent Research, Market & Sales Intelligence, Social Media Monitoring & Management and Custom Publishing solution.
Disclaimer: This report is published for general information only. High standards have been used for preparing this market research report;
Disclaimer: This report is published for general information only High standards have been used for preparing this market research report;
however, Netscribes, Inc. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole
property of Netscribes and prior permission is required for guidelines on reproduction.
MEDICAL DIAGNOSTICS – INDIA.PPT 30